Concomitant CCRT vs RT€¦ · T4 failures. 23 GTV underdosing GTV 3.4cc. 24 Marginal failures...

1

Nasopharyngeal Carcinoma: Management of localised disease

Dr Joseph Wee FRCRNational Cancer Centre SingaporeDuke-NUS Medical School, Singapore

2

• “I have no conflicts of interest to disclose.”

Disclosure

3

• Diagnostic work up• Staging• Radiotherapy• Follow up• Role of chemotherapy

Lecture Outline

4

• Naso-endoscope and Biopsy• Staging

– MRI– CT PNS, thorax, abdomen and Bone Scan or PET-CT

• Bloods– FBC, u/e/Cr, LFT– EBV DNA– Hepatitis B screening– ? LDH, CRP

• Planning CT

Diagnostic Workup

5

Staging – 7th edition

6

Staging – 8th edition

7

Staging – 8th edition

Lydiatt et al, CA 2017

Pan et al, Cancer 2016

8

Staging – 8th edition

9

Staging – 8th edition

Pan et al, Cancer 2016

Lydiatt et al, CA 2017

10

• Diagnostic work up• Staging• Radiotherapy• Follow up• Role of chemotherapy

Lecture Outline

11

RT - Planning CT

Lee et al, R&O 2018

12

IMRT

13

IMRT – Target Delineation - CTVp

IMRT – Target Delineation - CTVp

15

IMRT – Target Delineation - CTVn

16

IMRT – Target Delineation - CTVn

17

IMRT – Target Delineation - CTVn

18

IMRT – Target Delineation - OAR

19

IMRT – Target Delineation - OAR

20

• 70Gy in 33-35 fractions– Boost

• ?improve local control in 2D era (9% per Gy)• Brachytherapy, stereotactic boost• Risks of neurovascular complications

– IMRT era • Simultaneous integrated boost (SIB)

Total dose of RT

21

IMRT Outcomes

22

T4 failures

23

GTV underdosing

GTV <66.5Gy > 3.4cc

24

Marginal failures

70Gy to post NACT GTV64Gy to disappeared GTV

No survival detrimentBetter toxicity profile

25

GTVp

GTVp > 48cc

26

Late Toxicities

27

NACT to reduce late toxicities

28

How to avoid TLN

Two dosimetric features (D0.5cc and D10), is significantlyassociated with TLN status (P < .001)

rV40 < 10% or aV40 < 5cc

29

TLN – genetic susceptibility

30

Dysphagia

31

Hippocampus sparing RT

RTOG Atlas

Radiation-induced neurocognitive function decline

32

• Proton therapy– Kills less circulating T cells

Proton Therapy

33

Follow up EBV DNA

34

Salvage Surgery

35

Endoscopic Nasopharyngectomy

36

OS LRFS DMFS Gr 5 toxicity5 year 41% 72% 85% 33%

Salvage Re-RT

37

Selecting patients for re-RT

https://prancis.medlever.com/

38

Carbon ion for recurrent NPC

39

• Diagnostic work up• Staging• Radiotherapy• Follow up• Role of chemotherapy

Lecture Outline

40

• Early Stage – Stage 1, 2

Role of Chemotherapy : Can we individualize?

41

T1 – Good local and Distant control

Oral Oncology 2018

42

T2 - distant control

43

T2 - distant control

Limited to those with N1 disease

44

Benefit is Distant Control and not Loco-regional Control

45

LN > 3 cmEBV > 4000 copies

Summary (1) – Early Stage Tumours

• T1N0-1 (LN<3cm) - IMRT• T2N0-1 (LN<3cm) - IMRT• T1-2N1 (LN>3cm, EBV>4000) - ddp-IMRT

47

Standard of Care: Stage 3, 4

48

2 trials – results expected very soon

• HK 0501– Al-Sarraf vs Reverse Al-Sarraf

• SYSUCC– Induction Cis-Gem Cis-IMRT vs Cis-IMRT

Food for thought #2

49

• HK 0501– Induction is superior to Adjuvant

• SYSUCC– Induction is superior to CCRT

• When than can you omit Induction?

• Cis-Gem; Cis-Xeloda; Cis-5FU or TPF

• ?? Must it be ddp-RT – or should we be doing trials looking at ?5FU-RT or ?cyclo-RT

Scenario : If both trials are positive

50

Thank you